241 related articles for article (PubMed ID: 26893100)
1. Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factors.
Takahashi Y; Saga Y; Koyanagi T; Takei Y; Machida S; Taneichi A; Mizukami H; Sato Y; Matsubara S; Fujiwara H
Cancer Sci; 2016 May; 107(5):629-37. PubMed ID: 26893100
[TBL] [Abstract][Full Text] [Related]
2. The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.
Takahashi Y; Saga Y; Koyanagi T; Takei Y; Machida S; Taneichi A; Mizukami H; Sato Y; Matsubara S; Fujiwara H
Int J Oncol; 2015 Dec; 47(6):2057-63. PubMed ID: 26460696
[TBL] [Abstract][Full Text] [Related]
3. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
[TBL] [Abstract][Full Text] [Related]
4. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
[TBL] [Abstract][Full Text] [Related]
5. Tubulin carboxypeptidase activity of vasohibin-1 inhibits angiogenesis by interfering with endocytosis and trafficking of pro-angiogenic factor receptors.
Kobayashi M; Wakabayashi I; Suzuki Y; Fujiwara K; Nakayama M; Watabe T; Sato Y
Angiogenesis; 2021 Feb; 24(1):159-176. PubMed ID: 33052495
[TBL] [Abstract][Full Text] [Related]
6. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector.
Takei Y; Mizukami H; Saga Y; Yoshimura I; Hasumi Y; Takayama T; Kohno T; Matsushita T; Okada T; Kume A; Suzuki M; Ozawa K
Int J Cancer; 2007 Jan; 120(2):278-84. PubMed ID: 17066424
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.
Kohno T; Mizukami H; Suzuki M; Saga Y; Takei Y; Shimpo M; Matsushita T; Okada T; Hanazono Y; Kume A; Sato I; Ozawa K
Cancer Res; 2003 Aug; 63(16):5091-4. PubMed ID: 12941839
[TBL] [Abstract][Full Text] [Related]
8. PDGF BB induces VEGF secretion in ovarian cancer.
Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
[TBL] [Abstract][Full Text] [Related]
9. Vasohibin-1 inhibits angiogenesis and suppresses tumor growth in renal cell carcinoma.
Zhao G; Na R; Li L; Xiao H; Ding N; Sun Y; Han R
Oncol Rep; 2017 Aug; 38(2):1021-1028. PubMed ID: 28656230
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
Machida S; Saga Y; Takei Y; Mizuno I; Takayama T; Kohno T; Konno R; Ohwada M; Suzuki M
Int J Cancer; 2005 Mar; 114(2):224-9. PubMed ID: 15551349
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
12. Vasohibin-1 Is a Poor Prognostic Factor of Ovarian Carcinoma.
Sano R; Kanomata N; Suzuki S; Shimoya K; Sato Y; Moriya T; Shiota M
Tohoku J Exp Med; 2017 Oct; 243(2):107-114. PubMed ID: 29057763
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice.
Takei Y; Saga Y; Mizukami H; Takayama T; Ohwada M; Ozawa K; Suzuki M
Mol Cancer Ther; 2008 Mar; 7(3):704-11. PubMed ID: 18347155
[TBL] [Abstract][Full Text] [Related]
14. Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.
Koyanagi T; Suzuki Y; Komori K; Saga Y; Matsubara S; Fujiwara H; Sato Y
Cancer Sci; 2017 Mar; 108(3):512-519. PubMed ID: 28032401
[TBL] [Abstract][Full Text] [Related]
15. Possible action of vasohibin-1 as an inhibitor in the regulation of vascularization of the bovine corpus luteum.
Shirasuna K; Kobayashi A; Nitta A; Nibuno S; Sasahara K; Shimizu T; Bollwein H; Miyamoto A
Reproduction; 2012 Apr; 143(4):491-500. PubMed ID: 22367587
[TBL] [Abstract][Full Text] [Related]
16. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Manenti L; Riccardi E; Marchini S; Naumova E; Floriani I; Garofalo A; Dossi R; Marrazzo E; Ribatti D; Scanziani E; Bani M; Belotti D; Broggini M; Giavazzi R
Mol Cancer Ther; 2005 May; 4(5):715-25. PubMed ID: 15897235
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by
Huang B; Huang M; Li Q
Technol Cancer Res Treat; 2019; 18():1533033819879905. PubMed ID: 31757187
[TBL] [Abstract][Full Text] [Related]
18. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.
Masoumi Moghaddam S; Amini A; Morris DL; Pourgholami MH
Cancer Metastasis Rev; 2012 Jun; 31(1-2):143-62. PubMed ID: 22101807
[TBL] [Abstract][Full Text] [Related]
19. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
